TL;DR:
- AstraZeneca introduces Evinova, a standalone company offering digital clinical trial solutions.
- Evinova’s team of 300 experts spans nine countries, with tech tested in trials across 40+ nations.
- The “drug development suite” provides traditional and decentralized trial capabilities, simplifying patient participation.
- Evinova’s “unified trial solution” enables virtual visits and utilizes AI for trial design.
- Major CROs Parexel and Fortrea endorse Evinova’s solutions for their clients.
- Evinova’s revenue generation is expected from pharmaceutical collaborations.
- Evinova aligns with regulatory expectations for industry-wide collaboration.
Main AI News:
In a groundbreaking move, AstraZeneca has unveiled Evinova, a specialized subsidiary company aimed at revolutionizing the clinical trial landscape. Evinova boasts a team of 300 handpicked experts drawn from AstraZeneca’s global network, spanning nine countries. This strategic international presence underscores the extensive testing of Evinova’s cutting-edge technology in clinical trials sponsored by AstraZeneca, conducted across more than 40 countries.
Evinova’s core offering lies in its comprehensive “drug development suite,” a portfolio of trial solutions meticulously honed by AstraZeneca across its diverse disease areas. Through this platform, pharmaceutical companies, Contract Research Organizations (CROs), and clinical trial operators gain access to a spectrum of trial approaches, encompassing traditional, decentralized, and hybrid methodologies. This includes the seamless collection of data from connected medical devices at trial sites or directly from patients’ homes.
A standout feature of Evinova’s ecosystem is its “unified trial solution,” a game-changer for CROs aiming to conduct virtual visits. This encompasses services like delivering medications to patients, conducting telehealth appointments, and tracking biological samples. Evinova’s innovation lies in simplifying the patient experience, with participants needing just one user-friendly app that supports 80 languages.
Cristina Duran, CEO of Evinova, emphasized the importance of streamlining the patient journey in clinical trials, stating, “In a clinical trial, you can end up with six different apps and six different devices, and it’s extremely complex for the patient. So we’ve really worked on how to simplify that.”
However, the true power of Evinova lies in its utilization of artificial intelligence and machine learning algorithms. This empowers pharmaceutical companies to design bespoke trials, providing automatic cost estimates and pinpointing the most suitable countries and sites for operations.
Evinova has already garnered the support of industry heavyweights, including CRO giants Parexel and Fortrea, who have signed agreements to extend these groundbreaking solutions to their client base. Cristina Duran tantalizingly hinted at upcoming partnerships with pharmaceutical companies eagerly awaiting access to Evinova’s transformative capabilities.
Although Evinova operates as an autonomous entity, it remains an integral part of the AstraZeneca Group. Funded by its parent company, Evinova is poised to generate revenue from pharma collaborators in the near future.
Cristina Duran addressed concerns about sharing AstraZeneca’s proprietary trial expertise, asserting that this strategic move aligns with regulatory expectations. “My belief is that regulators do not want each pharma company to come with their own different solutions,” she remarked. “So across the industry, we will go much faster together, rather than individually. That’s why it’s a good place to do it now.” Evinova’s launch marks a pivotal moment in the pharmaceutical world, promising collaboration and innovation on an unprecedented scale.
Conclusion:
Evinova’s launch represents a significant advancement in the pharmaceutical market. By sharing its expertise and innovative solutions, AstraZeneca is fostering collaboration and standardization across the industry, which is likely to lead to more efficient and streamlined clinical trials. This move aligns with regulatory expectations and positions Evinova as a pioneer in the digital clinical trial landscape.
